Chipscreen's Chidamide Hits Endpoint in Aggressive PTCL
By Larry Schuster
Friday, May 24, 2013
SHANGHAI, China Chipscreen Biosciences Ltd., of Shenzhen, China, reported encouraging Phase II trial results for its Chidamide (formerly HBI-8000) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who had failed at least one prior systemic therapy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.